Echosens SAS, a subsidiary of Inner Mongolia Furui Medical Science Co., Ltd, has announced plans for an initial public offering (IPO) to list its shares on The Stock Exchange of Hong Kong Limited.

The company develops, manufactures, and markets non-invasive diagnostic products for hepatology.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Livongo Health plans to advance the launch of new products and services and expand into new market segments using a $44.5m series C financing round which was completed on 12 April.

Merck Global Health Innovation, Cowen Private Investments, Sapphire Ventures, Zaffre Investments, Wanxiang America Corporation and other investors such as General Catalyst Partners, Kleiner Perkins Caufield and Byers (KPCB), Draper Fisher Jurvtson (DFJ) and 7 wire Ventures participated in the financing.

Canadian medical device company Visiomed Group SA has announced the issue of bonds that are convertible into shares with equity warrants, in order to help launch large-scale commercial activities.

"The issue, with gross proceeds of $41.06m, was subscribed to by L1 Capital Corp."

The issue, with gross proceeds of $41.06m, was subscribed to by L1 Capital Corp.

iSTAR Medical SA, a medical device company based in Belgium, has completed a series B equity financing round for gross proceeds of €10m ($11.41m), which will be used to support product development and a CE-marking clinical study for its breakthrough glaucoma implant.